Crystal's MCW Coder HubICD-10-CM H47.292: Other Optic Atrophy, Left Eye
Quick reference
| Element | Value |
|---|---|
| ICD-10-CM code | H47.292 |
| Official descriptor | Other optic atrophy, left eye |
| Parent category | H47.29 - Other optic atrophy; H47.2 - Optic atrophy; H47 - Other disorders of optic nerve and visual pathways |
| ICD-10-CM chapter | H00-H59 (Diseases of the eye and adnexa) → H46-H47 (Disorders of optic nerve and visual pathways) |
| Laterality | Left eye (OS) |
| Billable | ✓ Yes (laterality-specific terminal code) |
| Clinical definition | Optic nerve degeneration that follows disc swelling (secondary) OR results from retinal/choroidal disease (consecutive); encompasses all optic atrophy types except primary, glaucomatous, and hereditary |
| Subtypes included | Secondary optic atrophy (post-papilledema, post-optic neuritis, post-AION); Consecutive optic atrophy (retinal disease); Temporal pallor of optic disc > |
| HCC status | Not a CMS-HCC code (manifestation; underlying cause may be HCC-relevant) |
| Chronic condition | Yes (irreversible optic nerve damage; permanent visual deficit) |
| Prognosis | Poor; represents end-stage damage; extent of recovery depends on underlying cause and duration |
Short description
H47.292 codes other optic atrophy of the left eye - a category encompassing optic nerve degeneration that does NOT fit the primary, glaucomatous, or hereditary classifications.
This includes:
- Secondary optic atrophy: Follows chronic optic disc swelling (papilledema, optic neuritis, AION) with indistinct disc margins, grey disc color, and glial proliferation.
- Consecutive optic atrophy: Results from inner retinal or choroidal disease (retinitis pigmentosa, central retinal artery occlusion, pan-retinal photocoagulation, retinochoroiditis) without preceding disc edema.
- Temporal pallor of optic disc (specified in H47.29 descriptor).
Full description (clinical context)
What is “other” optic atrophy?
H47.29x (“other optic atrophy”) is a catch-all category for optic nerve atrophy that doesn’t meet criteria for:
- Primary optic atrophy (H47.21x) - no preceding disc swelling
- Glaucomatous optic atrophy (H47.23x) - glaucoma-related cupping
- Hereditary optic atrophy (H47.22) - genetic causes
Two main subtypes under H47.29x:
1. Secondary optic atrophy
Definition: Optic atrophy that follows chronic optic disc swelling such as papilledema, optic neuritis, or anterior ischemic optic neuropathy (AION).
Pathophysiology:
- Optic nerve fibers exhibit marked degeneration with profuse glial tissue proliferation.
- Optic nerve head architecture is lost.
- Disc margins become indistinct/blurred (key distinguishing feature from primary atrophy).
- Disc color is grey (not white as in primary atrophy).
- Retinal vessels may be sheathed or show peripapillary gliosis.
Common causes of preceding disc swelling:
Papilledema (chronic elevated intracranial pressure):
- Idiopathic intracranial hypertension (IIH) - most common cause; typically young obese females; bilateral papilledema; headache; pulsatile tinnitus; transient visual obscurations.
- Brain tumors (glioblastoma, meningioma, metastases) causing mass effect and increased ICP.
- Cerebral venous sinus thrombosis - thrombosis of sagittal, transverse, or sigmoid sinuses impairs CSF drainage.
- Hydrocephalus - obstructive or communicating.
- Meningitis/encephalitis - infectious or inflammatory causes of increased ICP.
- Trauma - intracranial hemorrhage, subdural hematoma, cerebral edema.
Mechanism of vision loss in papilledema:
- Increased ICP transmitted via optic nerve sheath → compression of nerve axons.
- Axoplasmic flow stasis → intraneuronal ischemia → RGC axon death.
- If untreated, chronic papilledema evolves to secondary optic atrophy with permanent vision loss.
- Visual field defects in papilledema: enlarged blind spot initially, then nerve fiber bundle defects (arcuate scotomas, nasal steps); central vision typically spared until late stages.
Optic neuritis (inflammatory demyelination):
- Multiple sclerosis (MS) - most common cause; 50% of MS patients develop optic neuritis; 50% of optic neuritis patients later diagnosed with MS.
- Neuromyelitis optica spectrum disorder (NMOSD) - severe bilateral sequential optic neuritis; anti-AQP4 antibodies; worse prognosis than MS-related ON.
- Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) - often presents with optic neuritis; bilateral; recurrent.
- Chronic relapsing inflammatory optic neuropathy (CRION) - steroid-responsive; recurs with steroid taper; requires long-term immunosuppression.
- Infectious - syphilis, Lyme disease, tuberculosis, herpes zoster.
- Sarcoidosis - granulomatous inflammation.
Optic neuritis features:
- Acute painful vision loss (pain with eye movement - 92% of cases).
- Optic disc swelling (papillitis in 35%) or retrobulbar (65% with normal-appearing disc initially).
- Central scotoma most common visual field defect.
- Relative afferent pupillary defect (RAPD).
- Color vision deficiency (red desaturation).
- Vision recovery: 93% recover to ≥20/40 within 1 year; but residual optic atrophy common with permanent deficits in contrast sensitivity, color vision, and visual fields.
Anterior ischemic optic neuropathy (AION) - after acute phase:
- Initial presentation: Acute painless vision loss + disc swelling + altitudinal visual field defect.
- Evolution: Disc swelling resolves over 6-8 weeks → optic atrophy develops.
- Non-arteritic AION (NAION): Risk factors include diabetes, hypertension, sleep apnea, “disc at risk” (small cup-to-disc ratio).
- Arteritic AION (AAION): Giant cell arteritis; requires urgent high-dose steroids to prevent fellow eye involvement.
2. Consecutive optic atrophy
Definition: Optic atrophy associated with diseases of the inner retina or its blood supply without preceding optic disc swelling.
Pathophysiology:
- Retrograde degeneration of RGC axons after retinal/choroidal pathology destroys the RGCs.
- Optic disc is waxy pale with normal disc margins (distinguishes from secondary atrophy).
- Marked attenuation of retinal arteries.
- Normal physiologic cup preserved.
Common causes:
Retinitis pigmentosa (RP):
- Hereditary progressive retinal degeneration.
- Rod-cone dystrophy → night blindness, peripheral vision loss, tunnel vision.
- Fundus: bone spicule pigmentation, attenuated vessels, waxy disc pallor.
- Leads to consecutive optic atrophy as RGCs die.
Central retinal artery occlusion (CRAO):
- Acute painless vision loss (often on awakening).
- Fundus findings: Cherry-red spot (90%), retinal opacity/whitening (58%), arterial attenuation (32%), optic disc edema initially (22%).
- Mechanism: Embolic (carotid source most common) or thrombotic occlusion → complete retinal ischemia → RGC death within 90-100 minutes of onset.
- Prognosis: Poor; 2/3 of patients end with ≤20/400 vision; only 1/6 achieve ≥20/40.
- Late findings: Optic disc atrophy develops weeks after acute event.
- Bilateral CRAO rare; consider CNS lymphoma with optic nerve infiltration.
Extensive pan-retinal photocoagulation (PRP):
- Laser treatment for proliferative diabetic retinopathy or retinal vascular occlusions.
- Destroys peripheral retina → reduces metabolic demand → prevents neovascularization.
- Side effects: peripheral visual field loss, night vision reduction, optic disc pallor/atrophy.
Extensive retinochoroiditis:
- Toxoplasmosis, cytomegalovirus, syphilis, tuberculosis.
- Chorioretinal scarring with RGC loss → consecutive atrophy.
Pathological myopia:
- Extreme elongation of globe with posterior staphyloma.
- Choroidal atrophy, lacquer cracks, myopic macular degeneration.
- Optic disc changes with peripapillary atrophy.
Temporal pallor of optic disc
Temporal pallor is specifically mentioned in H47.29 descriptor.
Significance:
- Papillomacular bundle damage (temporal disc fibers supply macula).
- Causes central or centrocecal scotomas and reduced visual acuity.
- Seen in: Optic neuritis (MS), chiasmal compression (pituitary tumor with band atrophy), toxic/nutritional optic neuropathies, dominant optic atrophy.
Clinical presentation of H47.292 conditions
Symptoms:
- Progressive or sudden vision loss (depends on underlying cause).
- Central vision loss (if papillomacular bundle involved).
- Peripheral visual field defects (if nerve fiber layer damaged).
- Color vision defects.
- Contrast sensitivity loss.
- Pain (if associated with optic neuritis or increased ICP).
Exam findings (secondary optic atrophy):
- Optic disc appearance:
- Grey/pale disc color (not white).
- Indistinct/blurred disc margins (glial tissue overgrowth).
- Loss of optic nerve head architecture.
- Peripapillary gliosis.
- Sheathed or attenuated vessels (may be present).
- RAPD if unilateral or asymmetric.
- Reduced visual acuity.
- Visual field defects (depends on pattern of damage).
Exam findings (consecutive optic atrophy):
- Optic disc appearance:
- Waxy pale disc (yellowish-white).
- Normal/sharp disc margins (no gliosis).
- Marked attenuation of retinal arteries.
- Normal physiologic cup preserved.
- Underlying retinal disease visible (bone spicules in RP, retinal whitening/cherry-red spot in CRAO, chorioretinal scars, etc.).
Coding specifics (coder workflow)
Code structure breakdown
| Character position | Value | Meaning |
|---|---|---|
| 1st | H | Diseases of the eye and adnexa |
| 2nd-3rd | 47 | Other disorders of optic nerve and visual pathways |
| 4th | .2 | Optic atrophy |
| 5th | 9 | Other subtype (not primary, not glaucomatous, not hereditary) |
| 6th | 2 | Left eye |
When to code H47.292
Use H47.292 when:
- Provider documents “secondary optic atrophy” of left eye.
- Provider documents “consecutive optic atrophy” of left eye.
- Provider documents “other optic atrophy” or “temporal pallor” of left eye.
- Optic atrophy follows documented history of papilledema, optic neuritis, or AION.
- Optic atrophy is associated with retinal disease (retinitis pigmentosa, CRAO, extensive PRP, retinochoroiditis).
- Optic disc shows grey color with indistinct margins (secondary) OR waxy pallor with underlying retinal pathology (consecutive).
Supporting documentation phrases:
- “Secondary optic atrophy OS following chronic papilledema.”
- “Optic atrophy left eye sequela of optic neuritis.”
- “Consecutive optic atrophy OS due to central retinal artery occlusion.”
- “Temporal pallor of left optic disc.”
- “Grey optic disc with blurred margins consistent with secondary atrophy OS.”
When NOT to code H47.292 (use other codes)
Do not use H47.292 when:
| Condition | Use instead | Reason |
|---|---|---|
| Right eye affected | H47.291 | Laterality mismatch < |
| Both eyes affected | H47.293 | Bilateral other optic atrophy |
| Laterality not specified | H47.299 | Unspecified eye (avoid when laterality known) |
| Primary optic atrophy (no preceding disc swelling) | H47.212 (left eye) | “Primary” designation requires sharp disc margins, no prior edema |
| Glaucomatous optic atrophy | H47.232 (left eye) | Glaucoma-related atrophy |
| Hereditary optic atrophy | H47.22 | Genetic causes (Kjer’s, LHON) |
| Unspecified optic atrophy | H47.20 | Mechanism not documented > |
Critical distinction: H47.292 vs H47.212
| Feature | H47.212 (Primary atrophy OS) | H47.292 (Other/secondary atrophy OS) |
|---|---|---|
| Preceding disc swelling | NO - no history of papilledema/neuritis/AION | YES - follows chronic disc edema |
| Disc margins | Sharp, well-demarcated | Blurred, indistinct (glial proliferation) |
| Disc color | White/pale | Grey (secondary) or waxy (consecutive) |
| Retinal vessels | Normal caliber | May be sheathed/attenuated |
| Optic disc architecture | Preserved | Lost (secondary) |
| Causes | Compression, ischemic (post-acute), hereditary, traumatic, toxic | Post-papilledema, post-neuritis, post-AION (secondary); retinal disease (consecutive) |
Sibling codes (same H47.29 family)
| ICD-10-CM | Description | Use when | Billable |
|---|---|---|---|
| H47.29 | Other optic atrophy (category) | Non-billable parent | ✗ No |
| H47.291 | Other optic atrophy, right eye | Right eye | ✓ Yes |
| H47.292 | Other optic atrophy, left eye | Left eye (THIS NOTE) | ✓ Yes |
| H47.293 | Other optic atrophy, bilateral | Both eyes | ✓ Yes |
| H47.299 | Other optic atrophy, unspecified eye | Avoid when laterality documented | ✓ Yes |
Related codes (H47.2 family)
| ICD-10-CM | Description | Use when |
|---|---|---|
| H47.2 | Optic atrophy (category) | Non-billable parent |
| H47.20 | Unspecified optic atrophy | Mechanism not documented |
| H47.212 | Primary optic atrophy, left eye | No preceding disc swelling, sharp margins |
| H47.22 | Hereditary optic atrophy | Dominant optic atrophy, LHON, OPA variants |
| H47.232 | Glaucomatous optic atrophy, left eye | Glaucoma-related left eye |
| H47.292 | Other optic atrophy, left eye | Secondary/consecutive left (THIS NOTE) |
HCC information (risk adjustment)
H47.292 is NOT a CMS-HCC code.
Optic atrophy is a manifestation/sequela of underlying disease processes rather than a chronic systemic condition that drives risk adjustment.
However, the underlying etiology causing optic atrophy may be HCC-relevant:
- Multiple sclerosis (G35.-) causing optic neuritis → HCC-weighted.
- Neuromyelitis optica spectrum disorder (G36.0) with severe optic neuritis.
- Brain tumors (C71.x, D33.x) causing papilledema.
- Idiopathic intracranial hypertension (G93.2) - not HCC but document for clinical picture.
- Giant cell arteritis (M31.6) causing AAION.
- Diabetes mellitus (E08-E13) with proliferative diabetic retinopathy requiring extensive PRP.
Best practice:
- Code H47.292 to document the optic nerve damage manifestation.
- Always code the underlying condition separately when documented for complete clinical picture and potential HCC capture.
- Link optic atrophy to underlying cause in documentation (e.g., “Secondary optic atrophy OS due to chronic papilledema from idiopathic intracranial hypertension”).
Documentation requirements (work checklist)
Essential elements for H47.292
To support accurate coding and payer scrutiny: [1120][1161][896]
-
Explicit diagnosis statement
- “Secondary optic atrophy OS” OR “Consecutive optic atrophy OS” OR “Other optic atrophy OS.”
- Specify “secondary” or “consecutive” when applicable to clarify subtype.
-
Laterality clearly stated
- “Left eye” or “OS” must be documented.
-
Optic disc appearance described
- For secondary atrophy: Grey disc color, indistinct/blurred margins, loss of disc architecture, peripapillary gliosis, sheathed vessels (if present). [1120]
- For consecutive atrophy: Waxy pale disc, normal/sharp margins, marked arterial attenuation, underlying retinal pathology visible. [1120]
-
History of preceding disc swelling documented (for secondary atrophy)
- “History of papilledema” / “History of optic neuritis” / “History of AION.”
- Document resolution of disc swelling with subsequent atrophy development.
-
Visual function documentation
- Visual acuity OS: Best corrected VA.
- RAPD: Present or absent.
- Visual field defects: Pattern (enlarged blind spot, arcuate scotoma, central scotoma, altitudinal defect).
- Color vision deficits.
-
Underlying etiology documented and coded separately [1120]
- For secondary atrophy: Papilledema (H47.10-H47.13), optic neuritis (H46.x), AION (H34.23x), increased ICP (G93.2), brain tumor, etc.
- For consecutive atrophy: Retinitis pigmentosa (H35.52), CRAO (H34.1x), status post extensive PRP (Z98.89 + diabetic retinopathy code), retinochoroiditis, etc.
-
Diagnostic testing performed
- OCT optic nerve: Document RNFL thickness (reduced), disc morphology.
- Visual fields: Document pattern and severity of defects.
- VEP: Decreased amplitude or absent P100 (confirms optic nerve dysfunction).
- MRI brain/orbits: If papilledema, optic neuritis, or compressive lesion.
- Fundus photography: Document disc appearance, vascular changes, retinal pathology.
-
Chronicity and timeline
- “Chronic secondary optic atrophy following 2-year history of papilledema.”
- “Optic atrophy developed 8 weeks after acute optic neuritis episode.”
- Establishes temporal relationship between cause and effect.
Common auditor red flags
- “Optic atrophy” without specifying primary/secondary/consecutive/glaucomatous → should query for specificity; default to H47.20 (unspecified). [896]
- Documented history of papilledema/optic neuritis but coded as H47.212 (primary) → this is H47.292 (secondary), not primary. [1120]
- No documentation of disc margins or color → cannot distinguish primary vs secondary without exam description.
- Underlying cause not coded separately → missed documentation of potentially HCC-relevant diagnosis.
- “Temporal pallor” coded as H47.212 (primary) → temporal pallor is listed under H47.29 (other); use H47.292 for left eye. [896]
Associated CPT codes (common pairings)
E/M and comprehensive eye exam codes
| CPT | Description | Context for H47.292 |
|---|---|---|
| 99202-99205 | New patient office visit | Initial evaluation of vision loss/optic atrophy [722] |
| 99212-99215 | Established patient visit | Follow-up for known optic atrophy [722] |
| 92002-92004 | New ophthalmological services | Comprehensive eye exam for optic nerve evaluation [722] |
| 92012-92014 | Established ophthalmological services | Ongoing optic atrophy monitoring [722] |
Optic nerve diagnostic imaging
Optical Coherence Tomography (OCT) for optic atrophy evaluation:
| CPT | Description | Clinical use |
|---|---|---|
| 92133 | OCT posterior segment, optic nerve | Primary test for optic atrophy - RNFL thickness, disc morphology [1139] |
| 92134 | OCT posterior segment, retina | Ganglion cell layer analysis; macular thinning |
| 92250 | Fundus photography | Document disc appearance (grey vs waxy pallor), margins (sharp vs blurred), vascular changes; serial photos for progression |
OCT findings in secondary/consecutive atrophy:
- Reduced RNFL thickness (confirms axonal loss).
- Disc morphology: Loss of architecture in secondary atrophy; preserved cup in consecutive atrophy.
- Macular OCT: Ganglion cell-inner plexiform layer (GCIPL) thinning.
Visual field testing
| CPT | Description | Use in H47.292 |
|---|---|---|
| 92081 | Visual field examination, limited | Screening confrontation fields |
| 92082 | Visual field examination, intermediate | Humphrey 24-2 or 30-2 - documents pattern/severity |
| 92083 | Visual field examination, extended | 10-2 for central defects; Goldmann perimetry |
Visual field patterns by cause:
- Papilledema: Enlarged blind spot initially; nerve fiber bundle defects (arcuate, nasal step) with chronic papilledema. [1164]
- Optic neuritis: Central or centrocecal scotoma. [1104]
- AION: Altitudinal defect (superior or inferior). [889]
- CRAO: Dense central scotoma or profound generalized depression. [1143]
Electrophysiology testing
| CPT | Description | Findings in H47.292 |
|---|---|---|
| 95930 | Visual evoked potential (VEP) | Decreased amplitude or absent P100 (axonal loss); increased latency (demyelination from optic neuritis) [1104] |
VEP utility:
- Confirms optic nerve dysfunction objectively.
- Optic neuritis: Prolonged P100 latency (>120 ms) from demyelination; may persist even after visual recovery. [1104]
- Secondary atrophy: Severely reduced or absent amplitude.
Advanced imaging
| CPT | Description | Indication for H47.292 workup |
|---|---|---|
| 70450-70453 | CT head/orbits without/with contrast | Trauma, sinus disease, orbital mass |
| 70540-70543 | MRI brain without/with contrast | Papilledema workup (brain tumor, hydrocephalus, venous sinus thrombosis); optic neuritis (enhancement with gadolinium, MS plaques); chiasmal lesions [1104] |
| 70540-70543 | MRI orbits with fat suppression | Optic neuritis detection - 95% sensitivity within 20 days; T2/STIR detects lesions in 89% [1104] |
| 70551-70553 | MRI brain with/without contrast | Multiple sclerosis evaluation - periventricular white matter lesions, Dawson fingers [1104] |
Lumbar puncture (for papilledema)
| CPT | Description | Use in H47.292 secondary to papilledema |
|---|---|---|
| 62270 | Spinal puncture, lumbar, diagnostic | Measure opening pressure (elevated >25 cm H₂O in IIH); CSF analysis to rule out meningitis/encephalitis; therapeutic LP reduces ICP temporarily [1164][1174] |
Fluorescein angiography
| CPT | Description | Use in H47.292 |
|---|---|---|
| 92235 | Fluorescein angiography | Document retinal vascular occlusion (CRAO - absent arterial filling), optic disc leakage (papilledema, optic neuritis), chorioretinal scars [1176] |
Treatment overview (coding context)
Other optic atrophy is IRREVERSIBLE - treatment focuses on addressing the underlying cause to prevent further damage and protect the fellow eye. [1120][1172]
By underlying etiology:
Secondary optic atrophy from papilledema
Goal: Reduce intracranial pressure urgently to prevent further optic nerve damage. [1164][1172][1174][1177]
Medical management: [1172][1174][1177]
- Acetazolamide (Diamox) 500 mg PO BID to 1000 mg PO BID (first-line for IIH) - carbonic anhydrase inhibitor reduces CSF production. [1174]
- Topiramate or furosemide (Lasix) - second-line agents if acetazolamide intolerant. [1174]
- Weight loss (if obese) - cornerstone of IIH treatment; 5-10% weight loss significantly reduces ICP. [1164][1172]
- IV methylprednisolone 250 mg QID or 1 gram daily × 3 days (for acute severe papilledema with vision loss). [1177]
Surgical management: [1172][1174]
- Optic nerve sheath fenestration (ONSF) - for predominantly visual symptoms; creates window in optic nerve sheath to decompress nerve; protects vision but doesn’t improve headaches. [1164][1174]
- CSF diversion procedures (ventriculoperitoneal shunt, lumboperitoneal shunt) - for headaches ± visual loss; reduces ICP systemically. [1172][1174]
- Dural venous sinus stenting - for patients with venous sinus stenosis and high pressure gradient. [1174]
- Lumbar drain - temporary measure while awaiting definitive surgery. [1174]
Treat underlying cause of papilledema:
- Brain tumor → neurosurgical resection/radiation.
- Venous sinus thrombosis → anticoagulation.
- Hydrocephalus → shunt placement.
- Meningitis → antimicrobial therapy.
Secondary optic atrophy from optic neuritis
Acute phase treatment: [1104][1175]
- High-dose IV methylprednisolone 1 gram daily × 3-5 days followed by oral prednisone taper.
- Speeds visual recovery but does NOT improve final visual outcome. [1104]
- Reduces risk of MS development in following 2 years (if MRI shows demyelinating lesions) but effect disappears by year 3. [1104]
- Avoid oral prednisone alone - Optic Neuritis Treatment Trial (ONTT) showed oral prednisone increases recurrence risk. [1104]
Severe/refractory cases: [1175]
- Plasmapheresis (plasma exchange) - for neuromyelitis optica, MOGAD, or severe MS-related ON not responding to steroids; perform within 6 weeks of onset. [1175]
- IVIG (intravenous immunoglobulin) - alternative to plasmapheresis.
Long-term MS management: [1104][1175]
- Disease-modifying therapies (DMTs): Beta-interferon, glatiramer acetate, natalizumab, ocrelizumab, etc. - reduce MS relapse rate and prevent future ON episodes.
- For NMOSD: Azathioprine, rituximab, eculizumab (avoid beta-interferon and glatiramer as they worsen NMOSD). [1175]
Optic nerve regeneration trials: [1175]
- Erythropoietin and simvastatin show promise in pilot studies for promoting optic nerve recovery.
Secondary optic atrophy from AION
Arteritic AION (giant cell arteritis): [1170]
- Urgent high-dose IV methylprednisolone 1000 mg daily × 3-5 days followed by oral prednisone 60-80 mg daily, taper over ~1 year.
- Temporal artery biopsy within 1-2 weeks (but do not delay treatment).
- Goal: Prevent fellow eye involvement (risk of bilateral blindness without treatment).
- Treatment does NOT recover lost vision in affected eye. [1170]
Non-arteritic AION (NAION): [1170]
- No proven treatment for NAION (optic nerve decompression, hyperbaric oxygen, levodopa, aspirin all lack evidence).
- Risk factor modification: Control diabetes, hypertension, hyperlipidemia, sleep apnea.
- Aspirin may reduce fellow eye involvement risk (controversial).
Consecutive optic atrophy from retinal disease
Retinitis pigmentosa:
- No cure; management supportive (low vision aids, vitamin A supplementation controversial, genetic counseling).
Central retinal artery occlusion: [1143][1178]
- Acute treatment (within 90-100 minutes): Ocular massage, anterior chamber paracentesis, hyperbaric oxygen, IV thrombolysis (controversial; limited evidence).
- Once atrophy developed: Irreversible; focus on stroke prevention (carotid evaluation, antiplatelet therapy, cardiovascular risk modification). [1143]
Post-PRP consecutive atrophy:
- Prevention: Minimize laser spots when possible; titrate PRP dose.
- Once atrophy present: Irreversible; low vision rehabilitation.
Supportive care for all H47.292 patients
- Low vision services: Magnification devices, contrast enhancement, occupational therapy. [1120]
- Driving assessment if binocular visual fields inadequate.
- Protective eyewear for fellow eye (if unilateral).
- Monitor fellow eye closely - many causes of optic atrophy can be bilateral or sequential.
Sample ICD-10 combinations (work scenarios)
Scenario 1: Secondary optic atrophy OS from chronic papilledema (IIH)
ICD-10-CM codes:
- H47.292 - Other optic atrophy, left eye (secondary atrophy)
- G93.2 - Idiopathic intracranial hypertension (benign intracranial hypertension)
- H47.12 - Papilledema associated with increased intracranial pressure, left eye (if papilledema still present)
- E66.01 - Morbid obesity due to excess calories (if applicable; IIH risk factor)
- H53.482 - Generalized contraction of visual field, left eye (if visual field defect present)
CPT:
- 99215 - Established patient visit, high complexity
- 92133 - OCT optic nerve (reduced RNFL OS, loss of disc architecture)
- 92082 - Visual fields (nerve fiber bundle defects OS)
- 70553 - MRI brain with contrast (r/o mass, venous sinus thrombosis)
- 62270 - Lumbar puncture (opening pressure 32 cm H₂O; elevated)
Rationale: Secondary optic atrophy (H47.292) is sequela of chronic papilledema from IIH (G93.2); code both conditions. [1120][1164]
Scenario 2: Secondary optic atrophy OS following optic neuritis in MS patient
ICD-10-CM codes:
- G35 - Multiple sclerosis (HCC-relevant primary diagnosis)
- H47.292 - Other optic atrophy, left eye (secondary to optic neuritis)
- Z87.19 - Personal history of other diseases of the digestive system (if remote history; or use H46.12 if subacute optic neuritis)
CPT:
- 99214 - Established patient visit
- 92133 - OCT optic nerve (temporal RNFL thinning OS)
- 95930 - VEP (prolonged P100 latency OS, reduced amplitude)
- 70553 - MRI brain with contrast (periventricular white matter lesions)
Rationale: MS (G35) is HCC diagnosis; optic atrophy (H47.292) is sequela of demyelinating optic neuritis; VEP confirms demyelinating pattern. [1104][1120]
Scenario 3: Consecutive optic atrophy OS from central retinal artery occlusion
ICD-10-CM codes:
- H47.292 - Other optic atrophy, left eye (consecutive atrophy)
- H34.10 - Central retinal artery occlusion, unspecified eye (or H34.12 if specifying left)
- I65.22 - Occlusion and stenosis of left carotid artery (if embolic source identified)
- I10 - Essential hypertension
- E11.9 - Type 2 diabetes mellitus without complications
CPT:
- 92014 - Comprehensive ophthalmological exam
- 92133 - OCT optic nerve (RNFL thinning OS; inner retinal thinning)
- 92235 - Fluorescein angiography (absent arterial filling OS during acute phase; if documenting prior findings)
- 93880 - Carotid duplex ultrasound (evaluate embolic source)
Rationale: Consecutive optic atrophy (H47.292) results from RGC death following CRAO; code both atrophy and CRAO; include vascular risk factors. [1120][1143]
Scenario 4: Secondary optic atrophy OS from brain tumor with papilledema
ICD-10-CM codes:
- C71.9 - Malignant neoplasm of brain, unspecified (or specific location code)
- H47.292 - Other optic atrophy, left eye
- H47.12 - Papilledema associated with increased intracranial pressure, left eye (if still present)
- G93.5 - Compression of brain (mass effect)
CPT:
- 99215 - Established patient visit
- 92133 - OCT optic nerve (reduced RNFL OS, grey disc)
- 92082 - Visual fields (enlarged blind spot, arcuate defects OS)
- 70553 - MRI brain with contrast (demonstrate tumor)
Rationale: Brain tumor (C71.9) caused increased ICP → papilledema → secondary optic atrophy (H47.292); code tumor first as underlying cause. [1120][1164]
Scenario 5: Consecutive optic atrophy OS from retinitis pigmentosa
ICD-10-CM codes:
- H35.52 - Pigmentary retinal dystrophy (retinitis pigmentosa)
- H47.292 - Other optic atrophy, left eye
- H53.482 - Generalized contraction of visual field, left eye (tunnel vision)
CPT:
- 92014 - Comprehensive ophthalmological exam
- 92133 - OCT optic nerve (waxy disc pallor OS, RNFL thinning)
- 92134 - OCT retina (inner/outer retinal layer thinning)
- 92082 - Visual fields (severe peripheral constriction OS)
- 95930 - VEP (reduced amplitude OS)
Rationale: Retinitis pigmentosa (H35.52) causes progressive RGC death → consecutive optic atrophy (H47.292); code both conditions. [1120]
Sample documentation (clinic note template)
Chief Complaint: Vision loss left eye / Follow-up optic atrophy OS.
HPI: [Age]-year-old [male/female] with secondary optic atrophy of the left eye [OR consecutive optic atrophy of the left eye] presenting for evaluation. Patient reports [onset/progression] vision loss OS.
History: Patient has documented history of [papilledema from idiopathic intracranial hypertension / optic neuritis from multiple sclerosis / central retinal artery occlusion / retinitis pigmentosa / etc.]. [Describe timeline: “Acute optic neuritis episode 6 months ago with disc swelling; swelling resolved but optic disc now pale grey with indistinct margins consistent with secondary atrophy.“]
Past Ocular History:
- Other optic atrophy, left eye (diagnosed [date]; type: secondary [or consecutive]; etiology: [specify])
- [Prior papilledema OS / Prior optic neuritis OS / CRAO OS [date] / Retinitis pigmentosa]
- [Other ocular history]
Past Medical History:
- [Idiopathic intracranial hypertension / Multiple sclerosis / Giant cell arteritis / Diabetes / Hypertension]
Medications:
- [Acetazolamide / DMTs for MS / Antiplatelet agents / etc.]
Exam:
- Visual Acuity:
- OD: [20/XX]
- OS: [20/XX, count fingers, hand motion, light perception]
- Pupils:
- RAPD present OS (if unilateral or asymmetric atrophy)
- Color Vision:
- OS: [Reduced/absent]
- Confrontation Visual Fields:
- OS: [Central scotoma / Enlarged blind spot / Arcuate defect / Altitudinal defect / Constricted]
- Dilated Fundus Exam - Left Eye:
- Optic Disc (Secondary atrophy pattern): Grey/pale disc color. Indistinct, blurred disc margins with peripapillary gliosis. Loss of optic nerve head architecture. Cup-to-disc ratio [X]. Retinal vessels [may be sheathed / attenuated]. No current disc edema (resolved from prior papilledema/neuritis). Findings consistent with secondary optic atrophy. OR
- Optic Disc (Consecutive atrophy pattern): Waxy pale disc. Sharp, well-defined disc margins. Marked attenuation of retinal arteries. Normal physiologic cup preserved. Findings consistent with consecutive optic atrophy.
- Macula: [Findings consistent with underlying retinal disease if consecutive atrophy]
- Periphery: [Bone spicule pigmentation if RP / Retinal whitening if CRAO / Chorioretinal scars]
- Dilated Fundus Exam - Right Eye:
- [Normal / Findings if fellow eye affected]
Ancillary Testing:
- OCT Optic Nerve (CPT 92133):
- OS: Reduced RNFL thickness - Average [XX µm]. [Loss of disc architecture if secondary / Preserved cup if consecutive]. Findings consistent with optic atrophy.
- OD: [Normal / Findings]
- Visual Fields (CPT 92082/92083):
- OS: [Pattern of defect: enlarged blind spot, central scotoma, arcuate, altitudinal, peripheral constriction]. MD [value] dB, PSD [value] dB.
- VEP (CPT 95930): [If performed]
- OS: Decreased amplitude / Absent P100 response [+ prolonged latency if demyelination]. Confirms optic nerve dysfunction.
- MRI Brain/Orbits: [If performed]
- [Findings: brain tumor, hydrocephalus, venous sinus thrombosis, MS plaques, optic nerve enhancement]
- Labs: [ESR/CRP if AAION / LP opening pressure if papilledema]
Assessment:
- Other optic atrophy, left eye (H47.292) - secondary [or consecutive] type
- [Underlying diagnosis] (specify code: G93.2 IIH, G35 MS, H34.12 CRAO, H35.52 RP, C71.x brain tumor, etc.)
- [Associated visual field defect code if applicable]
Etiology: [Sequela of chronic papilledema from IIH / Sequela of optic neuritis from MS / Consecutive to central retinal artery occlusion / Consecutive to retinitis pigmentosa / etc.]
Type: [Secondary optic atrophy - follows disc swelling from papilledema/optic neuritis/AION / Consecutive optic atrophy - retrograde degeneration from retinal disease]
Prognosis: Guarded; optic atrophy represents irreversible end-stage optic nerve damage. Vision loss is permanent. Focus on treating underlying condition and protecting fellow eye.
Plan:
- Treat underlying cause:
- [Papilledema: Continue acetazolamide 1000 mg PO BID; encourage weight loss; consider ONSF if progressive vision loss]
- [Optic neuritis: Continue MS disease-modifying therapy (specify); monitor for relapses]
- [CRAO: Carotid evaluation; antiplatelet therapy; cardiovascular risk modification]
- [RP: Low vision rehabilitation; genetic counseling; vitamin A supplementation consideration]
- Monitor fellow eye closely - risk of bilateral involvement.
- Low vision referral for adaptive devices (if significant vision loss).
- Repeat OCT and visual fields in [3-6 months] to monitor stability vs progression.
- Patient education provided regarding permanent nature of optic atrophy, importance of treating underlying condition, and warning signs requiring urgent evaluation.
ICD-10-CM:
- H47.292 - Other optic atrophy, left eye
- [Underlying cause code]
- [H53.4xx visual field defect code if applicable]
CPT:
- [92014 or appropriate E/M]
- 92133 - OCT optic nerve
- 92082 - Visual field examination
- [Other procedures as performed]
Billing & compliance pearls
- H47.292 is NOT HCC but underlying cause (MS, brain tumor, IIH) may be HCC-relevant or clinically significant - always code etiology separately. [1104][1120]
- “Secondary” or “consecutive” should be specified when known - clarifies atrophy subtype and supports H47.29x code selection. [1120]
- History of papilledema/optic neuritis must be documented to justify “secondary” designation; timeline establishes causality. [1120][1164]
- Disc margin appearance is KEY - blurred margins = secondary (H47.292); sharp margins with no prior swelling = primary (H47.212). [1120]
- OCT optic nerve (92133) supports diagnosis - RNFL thinning, disc morphology changes confirm atrophy; medical necessity. [1139]
- Laterality is mandatory - left eye = H47.292, right eye = H47.291, bilateral = H47.293; do NOT use H47.299 (unspecified) when laterality documented. [896]
- Temporal pallor specifically listed under H47.29 (other optic atrophy) descriptor - use H47.292 for left eye with temporal pallor. [896]
- Link atrophy to underlying cause in documentation - e.g., “Secondary optic atrophy OS due to chronic papilledema from idiopathic intracranial hypertension” improves coding accuracy and medical necessity justification. [1120]
- VEP (95930) useful for confirming optic nerve dysfunction - especially in optic neuritis cases to document demyelination pattern. [1104]
- Prevention of further damage is treatment goal - urgent treatment of papilledema, optic neuritis, or AION prevents progression to atrophy; document urgency for medical necessity. [1164][1172]
Key sources (compact format)
[1160]: ECGWaves H47.292 other optic atrophy left eye classification H47 optic nerve disorders
[1161]: AAPC H47.292 official descriptor WHO classification billable code left eye
[1162]: Unbound Medicine H47.292 other optic atrophy left eye billable terminal code
[1163]: FindACode H47.292 ICD-10-CM hierarchy diagnosis code
[896]: AAPC H47.29 other optic atrophy category temporal pallor descriptor child codes (H47.291-H47.299 laterality)
[1120]: NCBI StatPearls optic atrophy secondary follows disc swelling papilledema/optic neuritis/AION grey disc indistinct margins loss of architecture glial proliferation sheathed vessels consecutive retinal disease waxy pale normal margins arterial attenuation
[1159]: Papilledema optic disc swelling elevated ICP venous engorgement hemorrhage blurred margins Paton’s lines fibers engorged bulge anteriorly persistent swelling permanent visual impairment
[1164]: PMC papilledema epidemiology etiology clinical management intraneuronal ischemia axoplasmic flow stasis visual loss feared morbidity enlarged blind spot nerve fiber bundle defects treatment weight loss diuretics ONSF CSF diversion
[1166]: MedLink papilledema increased ICP presenting headaches tinnitus visual disturbances secondary optic atrophy nerve flattens white color unilateral bilateral anatomic differences optic canal lamina cribrosa perioptic subarachnoid space axoplasmic transport impairment
[1172]: Merck papilledema treatment underlying disorder acetazolamide topiramate surgery ventriculoperitoneal shunt ONSF venous sinus stenting secondary optic nerve atrophy vision loss if ICP not reduced
[1174]: EyeWiki papilledema acetazolamide IIHT trial topimarate furosemide surgical ONSF CSF diversion LP/VP shunt dural venous sinus stenting bariatric surgery lumbar drain
[1177]: TTUHSC papilledema acute visual loss acetazolamide methylprednisolone lumbar puncture drain ONSF shunting procedures
[1104]: Optic neuritis MRI orbits fat suppression gadolinium 95% detection T2-weighted STIR steroids high-dose IV methylprednisolone ONTT visual acuity restoration MS-associated spontaneous improvement 2-3 months corticosteroids reduce MS risk 2 years effect disappears year 3
[1175]: PMC optic neuritis diagnosis treatment plasmapheresis within 6 weeks CRION steroid-responsive azathioprine rituximab NMOSD NMO-spectrum erythropoietin simvastatin pilot trials optic nerve regeneration
[889]: ION ischemic optic neuropathy acute painless vision loss decreased VA VF defect color vision loss RAPD swollen optic nerve head posterior ION no initial disc edema subsequent atrophy
[1170]: PION posterior ischemic optic neuropathy treatment blood transfusions raise blood pressure within hours A-PION GCA steroids temporal artery biopsy prevent progression second eye involvement high-dose corticosteroids taper 1 year perioperative rapid transfusion prevention best way
[1143]: CRAO central retinal artery occlusion painless acute vision loss cherry-red spot 90% retinal opacity 58% pallor 39% arterial attenuation 32% disc edema 22% emboli plaque optic atrophy emboli carotid origin 25% ophthalmic artery narrowest part dura piercing re-canalization edema clear optic atrophy permanent loss 15 minutes irreversible damage 2/3 20/400 1/6 20/40
[1171]: Central retinal artery CRAO complete vision loss fovea not affected retina pale swollen opaque central fovea reddish choroid shows through cherry red spot funduscopy
[1176]: Bilateral CRAO CNS lymphoma optic nerve infiltration MRI cortical leptomeningeal involvement fundus fluorescein angiography whole-brain irradiation systemic chemotherapy progressive bilateral CRAO NLP vision
[1178]: PMC sudden consecutive bilateral amaurosis CRAO medical emergency stroke equivalent AHA typical fundoscopic cherry-red spot retinal opacity arterial attenuation disc edema OCT increased inner retina thickness disc swelling acute phase retinal atrophy thinning weeks arteritic CRAO worst prognosis AAION retina and ONH ischemia high-dose corticosteroid critical avoid bilateral blindness
[722]: HCPCS Level I CPT numeric Level II alphanumeric non-physician services ambulance prosthetic devices
[1139]: CMS billing coding ophthalmology posterior segment imaging H47.292 covered diagnosis
[1111]: DrChrono ICD-10 code lookup H47.291 right H47.292 left H47.293 bilateral H47.299 unspecified